Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Peel Hunt downgrades Admiral to 'sell'

(Sharecast News) - Peel Hunt has downgraded insurer Admiral Group, weighing on the shares, on a weaker outlook for UK motor underwriting margins. In a note published on Friday, the broker cut its rating to 'sell' from 'reduce', and upped its target price to 2,350p from 2,270p.

It said: "The outlook for UK motor underwriting margins is starting to deteriorate, albeit from a high base, as rates continue to soften.

"We believe discipline will be required across the UK motor market in the second half of 2025 to avoid a sharp deterioration in underwriting margins in 2026. Admiral has gained considerable market share in UK motor over the past two years and it should be interesting to see how far it will go to protect this."

It concluded: "We unwind our discounted cash flow model to end-2025 full year, which lifts our target price...and values Admiral at 12x 2026 P/E. In contrast, the stock currently trades at 18x 2026 P/E.

"Given the notable premium to our fair value assumption, and with around 30% downside to our new target price, we downgrade our rating from 'reduce' to 'sell'.

"While the dividend yield is attractive, we believe it is more than offset by the valuation premium at which the shares currently trade."

As at 0915 BST, shares in the blue chip were down 2% at 3,372p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.